Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials-Reference-Cited by-同舟云学术

Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials

Published:2022-10 Issue:4 Volume:87 Page:784-791
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Mendes-Bastos Pedro,Ladizinski Barry,Guttman-Yassky Emma,Jiang Ping,Liu John,Prajapati Vimal H.,Simpson Eric L.,Vigna Namita,Teixeira Henrique D.,Barbarot Sebastien

Funder

AbbVie Inc

Publisher

Elsevier BV

Subject

Dermatology

Reference24 articles.

1. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494);Parmentier;BMC Rheumatol,2018

2. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials;Guttman-Yassky;Lancet,2021

3. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial;Reich;Lancet,2021

4. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial;van Vollenhoven;Arthritis Rheumatol,2020

5. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study;Smolen;Lancet,2019

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small Molecule Therapy for Inflammatory Bowel Disease: JAK Inhibitors and S1PR Modulators;The Korean Journal of Gastroenterology;2024-08-25

2. Consideration of treatment goals and termination algorithm for adolescent atopic dermatitis using upadacitinib;Journal of Cutaneous Immunology and Allergy;2024-08-22

3. Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning;Clinical Gastroenterology and Hepatology;2024-08

4. Effectiveness and Safety of Upadacitinib for Adolescents with Atopic Dermatitis in a Real-World Setting;Clinical Drug Investigation;2024-07-16

5. Perioral dermatitis associated with JAK inhibitors: clinical aspects and management;International Journal of Dermatology;2024-05-30